These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18385898)

  • 1. Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism.
    Zitzmann M
    Asian J Androl; 2008 May; 10(3):364-72. PubMed ID: 18385898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men.
    Zitzmann M
    Nat Clin Pract Urol; 2007 Mar; 4(3):161-6. PubMed ID: 17347661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of testosterone replacement therapy.
    Zitzmann M
    Pharmacogenomics; 2009 Aug; 10(8):1341-9. PubMed ID: 19663677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men.
    Zitzmann M; Gromoll J; von Eckardstein A; Nieschlag E
    Diabetologia; 2003 Jan; 46(1):31-9. PubMed ID: 12637980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of androgen replacement on metabolism and physical performances in male hypogonadism.
    Zitzmann M; Nieschlag E
    J Endocrinol Invest; 2003 Sep; 26(9):886-92. PubMed ID: 14964442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central body fat changes in men affected by post-surgical hypogonadotropic hypogonadism undergoing testosterone replacement therapy are modulated by androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Buldreghini E; Lenzi A; Balercia G
    Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):908-13. PubMed ID: 24787905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor gene CAG repeat length in women with metabolic syndrome.
    Jääskeläinen J; Korhonen S; Kuulasmaa T; Kurl S; Niskanen L; Vanhala M; Hippeläinen M; Voutilainen R; Heinonen S
    Gynecol Endocrinol; 2008 Jul; 24(7):411-6. PubMed ID: 18645714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the CAG repeat androgen receptor polymorphism in andrology.
    Zitzmann M
    Front Horm Res; 2009; 37():52-61. PubMed ID: 19011288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of testosterone on body composition of the aging male.
    Mudali S; Dobs AS
    Mech Ageing Dev; 2004 Apr; 125(4):297-304. PubMed ID: 15063106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study.
    Stanworth RD; Akhtar S; Channer KS; Jones TH
    Eur J Endocrinol; 2014 Feb; 170(2):193-200. PubMed ID: 24165020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Gioia A; Biagioli A; Lenzi A; Balercia G
    J Endocrinol Invest; 2014 Apr; 37(4):393-400. PubMed ID: 24458833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip.
    Svartberg J; Agledahl I; Figenschau Y; Sildnes T; Waterloo K; Jorde R
    Int J Impot Res; 2008; 20(4):378-87. PubMed ID: 18480825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients.
    Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6208-17. PubMed ID: 15579779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone and body functions.
    Köhn FM
    Aging Male; 2006 Dec; 9(4):183-8. PubMed ID: 17178552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Length of androgen receptor-CAG repeats in fertile and infertile Egyptian men.
    Badran WA; Fahmy I; Abdel-Megid WM; Elder K; Mansour R; Kent-First M
    J Androl; 2009; 30(4):416-25. PubMed ID: 19168451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
    Miner M; Canty DJ; Shabsigh R
    Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deficiency in the aging male: a guide to diagnosis and testosterone replacement therapy.
    Raynor MC; Carson CC; Pearson MD; Nix JW
    Can J Urol; 2007 Dec; 14 Suppl 1():63-8. PubMed ID: 18163948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic, physical and lifestyle factors associated with androgen status: the Florey Adelaide Male Ageing Study (FAMAS).
    Atlantis E; Martin SA; Haren MT; O'Loughlin PD; Taylor AW; Anand-Ivell R; Ivell R; Wittert GA;
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):261-72. PubMed ID: 19178527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.